Abstract

Background: Postmenopausal osteoporosis (PMO) is a debilitating disease induced by estrogen deficiency characterized by bone loss and bone micro-architecture degradation contributing to fragility fractures. Osteopontin (OPN) has been found to be involved in bone turnover by activating the resorption process. Objectives: This study aim to evaluate the relationship between serum OPN levels and bone mineral density (BMD) for identification of female individuals at high risk of osteoporotic fractures. Methods: A total of eighty eight postmenopausal women (PMW) were recruited in this study. Densitometry results addressed cases of the study into 3 groups: thirty with osteoporosis, thirty with osteopenia and twenty eight PMW without complications as a control group. Serum OPN was measured by using Enzyme-Linked immunosorbent assay (ELISA) kits and BMD was obtained at lumbar spine and femoral neck by dual-energy X-ray absorptiometry (DEXA). Results: Osteopontin levels were significantly higher in osteoporotic group compared to osteopenic and control groups (P ˂ 0.001). Negative correlation was found between BMD and OPN in osteoporotic group. By using the Receiver Operating Characteristic (ROC) curve, the cutoff level of ≥ 10.294 ng/mL for OPN was chosen for suggesting osteoporosis which yield a sensitivity of 66.67 % and specificity of 96.43 %. Also, there were a significant increase in serum ALP levels in osteoporotic and osteopenic groups compared to control group while serum Ca failed to show a significant difference between the studied groups. In addition, serum TAC showed a significant decrease in osteoporotic group compared to control group. Conclusion: These findings suggest that the circulating OPN might play role in the pathophysiology of PMO. Its blood concentration can be used as a sensitive monitoring indicator for the early detection of osteoporosis independently of BMD.

Highlights

  • Postmenopausal osteoporosis (PMO) is a silent, asymptomatic bone disease where bone resorption exceeds bone formation

  • bone mineral density (BMD) values based on world health organization (WHO) criteria classified subjects into 3 groups: 30 osteoporosis, 30 osteopenia, and the remaining 28 were apparently normal

  • There were a significant increase in serum alkaline phosphatase (ALP) levels in osteoporotic and osteopenic groups compared to control group while serum Ca failed to show a significant difference between the studied groups

Read more

Summary

Introduction

Postmenopausal osteoporosis (PMO) is a silent, asymptomatic bone disease where bone resorption exceeds bone formation. It is characterized by decreased bone mass, disruption of bone microarchitecture and compromised bone strength, leading to fragility fractures. Dual-energy X-ray absorptiometry (DEXA) is recognized as the dominant, simple tool used to quantify BMD. It is the most preferred technique used in clinical practice that can diagnose osteoporosis (Lorente Ramos et al, 2012). Postmenopausal osteoporosis (PMO) is a debilitating disease induced by estrogen deficiency characterized by bone loss and bone micro-architecture degradation contributing to fragility fractures. Osteopontin (OPN) has been found to be involved in bone turnover by activating the resorption process

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call